AAV9 Vector Promoter for Cone Photoreceptor Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for gene delivery to the fovea in the retina are limited by the detachment of the macula during subretinal injections, which can lead to complications such as macular holes and reduced vision, and fail to effectively target cone photoreceptors in the foveal region.
Innovation Solution
A recombinant AAV9-derived vector with a modified VP1 capsid protein and a polynucleotide under the control of the pR1.7 promoter is used for subretinal delivery, allowing efficient transduction of cone photoreceptors in the fovea without detaching the region, using a distal bleb injection technique.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If subretinal injection is performed to deliver gene therapy to the fovea, then gene delivery efficacy is improved, but the risk of macular detachment and macular holes increases
Solution Approach 1:
The patent uses a specifically engineered AAV capsid (AAV2-7m8) as an intermediary delivery vehicle that can traverse the retinal layers without requiring direct subretinal injection into the fovea. The capsid is modified with peptides that enable it to bind to and enter photoreceptor cells from the vitreous cavity, thereby mediating gene delivery while avoiding mechanical disruption of the macula.
Solution Approach 2:
The patent segments the delivery approach by separating the injection site (vitreous cavity, peripheral to the fovea) from the target site (foveal photoreceptors). This allows gene delivery to be performed safely away from the vulnerable foveal region while still achieving therapeutic transduction of the target cells through the engineered viral vector's cell-specific tropism.
2Productivity
If subretinal injection is performed to deliver gene therapy to the retina, then transduction efficiency is improved, but surgical complexity and patient risk increase
Solution Approach 1:
The patent inverts the conventional delivery approach by injecting into the vitreous cavity (anterior/central compartment) rather than performing subretinal injection (posterior/external compartment). This reversal of the injection route simplifies the surgical procedure while the engineered AAV2-7m8 capsid directs the vector to the correct target cells through its modified cell-binding properties.
3Adaptability or versatility
If conventional AAV vectors are used for gene delivery, then broad tissue transduction is achieved, but specific targeting of cone photoreceptors is insufficient
Solution Approach 1:
The patent applies local quality by modifying the AAV capsid with specific peptide sequences that confer cell-type-specific binding properties. The AAV2-7m8 capsid is engineered with peptides that specifically recognize and bind to receptors on photoreceptor cell surfaces, thereby directing transduction preferentially to cones while maintaining the ability to transduce other retinal cells if needed.
Data Source
AI summary
Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.